X0306 4 2022-05-19 0 0001662774 Cortexyme, Inc. CRTX 0001639637 Smith Karen L. C/O CORTEXYME, INC. 269 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2022-05-19 4 A 0 24336 A 24336 D Employee Stock Option (right to buy) 0.55 2022-05-19 4 A 0 151799 A 2032-03-27 Common Stock 151799 151799 D Employee Stock Option (right to buy) 2.98 2022-05-23 4 A 0 1365449 0.00 A 2032-05-22 Common Stock 1365449 1365449 D On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. Received in the Merger in exchange for an employee stock option to acquire 1,667,000 shares of Novosteo common stock for $0.05 per share. /s/ Chris Lowe, Attorney-in-Fact for Karen L. Smith 2022-05-23